Ozempic (also known as Semaglutide or GLP-1 agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, cardiovascular. FDA-approved GLP-1 agonist (Ozempic/Wegovy/Rybelsus) with 15-21% weight loss and 20% cardiovascular risk reduction. Nausea common, NAION risk noted.
Semaglutide is an FDA-approved GLP-1 receptor agonist with 94% structural homology to human GLP-1, manufactured by Novo Nordisk as Ozempic (diabetes, 0.25-2mg weekly injection), Wegovy (obesity, up to 2.4mg weekly injection), and Rybelsus (diabetes, 3-14mg daily oral). Activates GLP-1 receptors in the gastrointestinal tract, pancreas, and brain to reduce appetite, delay gastric emptying, increase insulin release, and lower glucagon secretion. STEP trials demonstrated 14.9-17.4% mean weight loss at 68 weeks (2.4mg dose), with 69-79% achieving ≥10% weight loss.
Overview
STEP UP trial showed 20.7% weight loss with 7.2mg dose at 72 weeks.
SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiac events (HR 0.80) in patients with obesity and preexisting cardiovascular disease but without diabetes.
FDA-approved March 2024 for reducing cardiovascular death, heart attack, and stroke risk.
Also approved for metabolic-associated steatohepatitis (MASH).
Most common side effects are gastrointestinal (nausea affecting up to 20%, vomiting, diarrhea, constipation), typically transient and mild-to-moderate.
Notable concerns include possible gastroparesis, 85% increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), and thyroid cancer warnings from rodent studies (though human incidence <1%).
Available in both injection (89% bioavailability) and oral forms (0.4-1% bioavailability).
Gradual titration over 12-16 weeks minimizes gastrointestinal side effects.
Mechanism of action
Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
Reported effects
Effects reported in the literature and from preclinical models include:
- Subcutaneous semaglutide 2.4mg reduced body weight by about 11.45% versus placebo, and GLP-1/incretin-based therapy delivered within lifestyle interventions reduced weight by roughly 6-10 kg versus control across meta-analyses of randomized trials. [3][8][10] Phase III
- Once-daily oral semaglutide produced weight loss comparable to subcutaneous semaglutide and superior to placebo in the OASIS trials, supporting FDA approval of oral Wegovy for chronic weight management alongside cardiometabolic improvements. [7][9] FDA approved
- Semaglutide is FDA-approved for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, reducing liver enzymes and more than doubling the likelihood of steatohepatitis resolution without fibrosis progression, though fibrosis-stage improvement remains uncertain. [5][11][2][4] FDA approved
- Once-weekly semaglutide 1.0mg lowered HbA1c by about 0.64 percentage points and body weight by 4.38 kg versus other injectable therapies in type 2 diabetes, with lower hypoglycemia risk than basal insulin. [12] Phase III
- GLP-1 receptor agonists including semaglutide lowered the urinary albumin-to-creatinine ratio by roughly 28% alongside weight loss in patients with and without type 2 diabetes. [10] Phase III
- Semaglutide use in type 2 diabetes has been associated with an increased risk of non-arteritic anterior ischemic optic neuropathy in observational cohorts, with pooled hazard ratios of 2.37-3.36 and an 85% relative increase versus SGLT2 inhibitor initiators, though absolute risk remained small. [6][1] Anecdotal
Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal
Dosage and administration
Injectable
- Week 1-4: 0.25mg once weekly (subcutaneous)
- Week 5-8: 0.5mg once weekly
- Week 9-12: 1.0mg once weekly
- Week 13+: 2.0mg (Ozempic) or 2.4mg (Wegovy) maximum
- Higher dose: 7.2mg weekly (experimental, 20.7% weight loss)
Oral Rybelsus
- Days 1-30: 3mg daily on empty stomach
- Days 31-60: 7mg daily
- Day 61+: 14mg daily maximum
General
- Take oral form with ≤4oz water, wait 30 min before eating
- Gradual titration over 12-16 weeks reduces GI side effects
Natty status
Ozempic is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[13]
Research
The peptide has been the subject of 39 studies and reference works collected on this site. Additional bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- ^ NAION vision risk study
- ^ MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.
- ^ Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Recent review
- ^ GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review. Recent review
- ^ Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. Recent review
- ^ Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. Recent review
- ^ A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. Recent review
- ^ GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Recent review
- ^ Evidence-informed guidance for the clinical use of oral semaglutide in obesity management. Recent review
- a b Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis. Recent review
- ^ Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. Recent review
- ^ Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis. Recent review
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- Wikipedia article
- STEP 1 trial weight loss results
- SELECT trial cardiovascular outcomes
- STEP program comprehensive review
- Carpal tunnel surgery outcomes
- StatPearls comprehensive review
- Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
- Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis.
- Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.
- Swiss obesity clinical practice guidance.
- Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes.
- Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.
- Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.
- GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
- GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
- Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.
- Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
- Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
- Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
- GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.
- GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
- Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
- GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.
- [Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].
- Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.
- 10mg Semaglutide — commercial
- Bacteriostatic Water Reconstitution Solution 10ml — commercial
This page was last updated on August 4, 2026, at 00:42 (UTC).
Research last reviewed on August 4, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.